Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Terminated 2Completed 1

Sponsor Class

OTHER 5INDUSTRY 4NIH 3OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3Endocrine 3Genitourinary 1

Conditions

Carcinoma, Renal Cell 11Melanoma 10Carcinoma, Hepatocellular 7Brain Neoplasms 6Leukemia, Myeloid, Acute 5Glioblastoma 5Sarcoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia, Myelomonocytic, Acute 4Gliosarcoma 4Urinary Bladder Neoplasms 3Unspecified Adult Solid Tumor, Protocol Specific 3Thyroid Neoplasms 3Rectal Neoplasms 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Neoplasms 3Multiple Myeloma 3Lymphoma, Large B-Cell, Diffuse 3Liver Neoplasms 3Leukemia, Monocytic, Acute 3Leukemia, Megakaryoblastic, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia, Erythroblastic, Acute 3Leukemia, Eosinophilic, Acute 3Leukemia, Basophilic, Acute 3Hemangiosarcoma 3Colonic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Blast Crisis 3

Interventions

Magnetic Resonance Spectroscopy 9Specimen Handling 4Iodine-131 4Trastuzumab 3Thyrotropin Alfa 3Sorafenib 3Nivolumab 3Fluorodeoxyglucose F18 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3trametinib 2tipifarnib 2romidepsin 2omipalisib 2dabrafenib 2cabozantinib 2aldesleukin 2Triiodothyronine 2Sunitinib 2Ipilimumab 2Iodine-124 2CTLA-4 Antigen 2Bortezomib 2Biopsy 2vandetanib 1ulixertinib 1trastuzumab biosimilar HLX02 1tanespimycin 1sargramostim 1sapanisertib 1relatlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × Thyroid Neoplasms × Sorafenib × Clear all
NCT01502410 2018-06-26

Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Completed
20 enrolled 14 charts
EndocrineGenitourinaryHead & Neck

Thyroid Cancer, Papillary, Wilms Tumor, Thyroid Neoplasms

NCT00126568 2018-01-19

Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
20 enrolled 10 charts
EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

NCT00095693 2014-01-16

Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
25 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡